Emerging Therapies in the Management of HR+, HER2- Metastatic Breast Cancer - Episode 3

The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer

February 2, 2024

Laura Huppert, MD, and Yara Abdou, MD, discuss data from the MAINTAIN trial on ribociclib in combination with endocrine therapy in patients with metastatic breast cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: An Overview of HR+, HER2- Metastatic Breast Cancer

EP. 2: Overview of the Treatment Landscape for HR+, HER2- Advanced or Metastatic Breast Cancer

Now Viewing

EP. 3: The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer

EP. 4: Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy

EP. 5: CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer

EP. 6: The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer

EP. 7: The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer

EP. 8: Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer

EP. 9: Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer